Having established that the combination treatment targeted CEP55‐dependent cells, we treated a panel of 21 breast cancer lines with these agents and found mixed responses, but basal‐like, triple‐negative (TNBC) lines specifically responded to the combination treatment (Fig 6A). The gene discussed is CEP55; the disease is breast cancer.